system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Deoxyadenosines, Dose-Response Relationship, Drug, Drug Synergism, Humans, Hydroxyurea, Leukemia, T-Cell.
user
Does cordycepin/Hydroxyurea synergy allow low dosage efficacy of cordycepin in MOLT-4 leukemia cells? Context: Cordycepin requires the relatively toxic co-drug, deoxycoformycin, for full efficacy as an anticancer agent. We sought to improve cordycepin efficacy using other, less toxic co-drugs. We evaluated the ability of hydroxyurea (HU) to enhance the effects of cordycepin against MOLT-4 leukemia cells with the MTT cell viability assay. We determined the relationship of the combination drug treatment with CalcuSyn statistical analysis program according to the Chou-Talalay method. HU (50 microg/ml) was found to reduce the IC50 of cordycepin from 100 microM to 0.3 microM, a reduction similar to that observed for deoxycoformycin. CalcuSyn analysis of the cordycepin/HU combination revealed the dose effect as synergistic. Further statistical analysis demonstrated a clear synergy between the two drugs at a range of dosages.
assistant
HU was identified as a promising potential alternative for anti-cancer therapy with cordycepin, thus eliminating the need for the toxic deoxycoformycin. Final Decision: yes